When should medication for adult attention‑deficit/hyperactivity disorder be stopped?

When to Stop ADHD Medications in Adults

ADHD medication should not be routinely discontinued in adults who continue to experience clinically significant symptoms and functional impairment, as evidence demonstrates sustained benefit with long-term treatment and increased risk of adverse outcomes with discontinuation. 1

Evidence-Based Approach to Medication Continuation vs. Discontinuation

Primary Decision Framework

The decision to continue or stop ADHD medication should be based on ongoing symptom control and functional impairment, not arbitrary time limits. Randomized withdrawal studies provide clear evidence that discontinuation leads to symptom recurrence and functional decline within approximately 2 years 2.

Implement scheduled medication-free trial periods at regular intervals (typically annually) to reassess the ongoing need for treatment 2. This approach allows objective evaluation of whether medication continues to provide meaningful benefit.

When to Consider Stopping Medication

Stop or consider discontinuation when:

• Symptoms are in sustained remission without causing significant impairment in any life domain
• Severe cardiovascular concerns emerge, particularly hypertension or arterial disease, as longer cumulative use (>3 years) is associated with increased cardiovascular risk 3
• Intolerable side effects persist despite dose adjustments and medication trials
• Patient preference after informed discussion of risks and benefits

When to Continue Medication

Continue treatment indefinitely when:

• Symptoms cause persistent significant impairment in at least one domain (occupational, social, academic) 4
• Previous discontinuation attempts resulted in symptom recurrence and functional decline
• Patient demonstrates clear benefit in quality of life, work disability prevention, and psychiatric stability 5

Critical Monitoring Requirements

During maintenance treatment, establish a structured monitoring schedule 6:

• Monthly appointments until symptoms stabilize
• Systematic cardiovascular monitoring throughout treatment duration, with increased vigilance after 3 years of cumulative use given the 4% increased CVD risk per year of treatment 3
• Regular assessment of blood pressure, heart rate, and cardiovascular symptoms
• Specific inquiry about side effects including insomnia, appetite changes, headaches, and mood symptoms 6

Important Clinical Pitfalls

Avoid the assumption that medication must be discontinued after a certain duration. Many patients lack insight into their ADHD symptoms and may undervalue treatment benefits 1. Two-thirds of patients discontinue medication during adolescence despite ongoing symptoms, often with negative consequences 1.

Do not discontinue abruptly without a structured trial period. Use medication-free periods as opportunities to help patients recognize their most impairing symptoms and understand when resumption may be necessary 1.

Special Considerations for Long-Term Treatment

Evidence shows that methylphenidate and other stimulants provide substantial symptom reduction for approximately 2 years, though evidence for long-term advantages beyond symptom control (social functioning, academic achievement) remains limited and inconsistent 2. However, recent data demonstrates that lisdexamphetamine, methylphenidate, and amphetamines are associated with reduced psychiatric hospitalization, suicidal behavior, and work disability 5.

Balance cardiovascular risks against psychiatric and functional benefits. While cumulative use beyond 3 years shows increased cardiovascular risk (particularly hypertension with AOR 1.72 at 3-5 years) 3, discontinuation may lead to increased psychiatric morbidity and functional impairment 5.

Practical Algorithm

1. At each follow-up: Assess target symptoms, functional impairment, side effects, and cardiovascular parameters
2. Annually: Implement a planned medication-free trial period (typically during low-stress periods)
3. During trial: Monitor for symptom recurrence and functional decline
4. If symptoms return: Resume medication
5. If symptoms remain controlled: Consider extended discontinuation with close follow-up
6. After 3 years cumulative use: Intensify cardiovascular monitoring and explicitly discuss risk-benefit ratio